Preprint Review Version 1 This version is not peer-reviewed

Modafinil for Narcolepsy: A Systematic Review and Meta-Analysis of Its Effectiveness in Combating Daytime Sleepiness

Version 1 : Received: 29 September 2024 / Approved: 30 September 2024 / Online: 30 September 2024 (07:47:46 CEST)

How to cite: Mann, G. S.; Ramakrishnan, M.; Pakkam, M. L.; Sufiyan, N.; Kukadiya, R.; Girigosavi, K. B. Modafinil for Narcolepsy: A Systematic Review and Meta-Analysis of Its Effectiveness in Combating Daytime Sleepiness. Preprints 2024, 2024092363. https://doi.org/10.20944/preprints202409.2363.v1 Mann, G. S.; Ramakrishnan, M.; Pakkam, M. L.; Sufiyan, N.; Kukadiya, R.; Girigosavi, K. B. Modafinil for Narcolepsy: A Systematic Review and Meta-Analysis of Its Effectiveness in Combating Daytime Sleepiness. Preprints 2024, 2024092363. https://doi.org/10.20944/preprints202409.2363.v1

Abstract

Background: Narcolepsy is characterized by excessive daytime sleepiness (EDS) and episodes of cataplexy, frequently triggered by psychological stress, significant disturbances in sleep-wake cycles, pregnancy, or trauma. Modafinil is widely used as the preferred treatment due to its effectiveness in alleviating EDS, improving disease outcomes, and enhancing overall quality of life. Nonetheless, long-term safety and efficacy data are still lacking, underscoring the importance of future research to advance treatment options for narcolepsy. Aim: In our systematic review and meta-analysis, we aim to assess the effectiveness of Modafinil in the treatment of Narcolepsy. Methods: We searched in electronic databases (PubMed, Embase, Google Scholar, Scopus, Science Direct, Web of Science) was performed to identify cohort studies and randomized controlled trials (RCTs) up to 8th July 2024. Data extraction focused on baseline characteristics of the included studies and efficacy outcomes, including scores on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) . We performed the meta-analysis utilizing the Review Manager software, version 5.4. To assess the outcomes, we compared the Modafinil-treated group with the placebo group, employing the mean difference (MD) and a 95% confidence interval (CI) for statistical analysis. Result: In total, 3833 articles were identified for screening, with nine studies included in the systematic review and five in the meta-analysis. These studies involved 997 adult patients with Narcolepsy treated with Modafinil. MWT revealed a significant increase in total scores (MD= 3.56, 95% CI [2.25 to 4.86], p < 0.00001) and ESS revealed a significant decrease in scores (MD= -3.34, 95% CI [-4.13 to -2.56], p < 0.00001). Conclusion: The research emphasizes the potential of Modafinil in alleviating EDS associated with Narcolepsy. While the results are promising, they are based on short term scale studies. It is crucial to undertake larger-scale, extended-duration, placebo-controlled studies that include a broad range of demographic populations. These trials are essential to confirm the efficacy, verify the safety profile, and fine-tune dosing strategies to maximize the long-term therapeutic benefits.

Keywords

Modafinil; Narcolepsy; Daytime sleepiness; CNS stimulant

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.